In summary, EGFR inhibitors significantly induced autophagy activities in human bladder cancer cells, and concomitant suppression of autophagy activities enhanced the anti-cancer effects of EGFR inhibitors, such as lapatinib and gefitinib. The gene discussed is EGFR; the disease is urinary bladder cancer.